antihypertensive therapy holds promise for isolated systolic hypertension in the elderly

1
2 AIit.ihyper,tensive therapy holds promise for isolated systolic hypertension in- the iHderly . . .. The prevalence of isolated systolic hypertension ranges from ' 6% in 60-year-olds to 180/0 inpatients aged>' 80 years . . Several studies have .shown the efficacy of antihypertensive therapy in elderly patients with isolated systolic hypertension bufthe effect on the risk- of cardiovascular events and adverse metabolic effects was unclear. Results of a 5-yearfollow-up of the Systolic Hypertension in the Elderly Programme [see Therapy section, this issue. p 10] confirm the efficacy and safety of chlorthalidone therapy in patients aged); 60 years with isolated systolic hypertension. The risk of stroke in these patients was found to be significantly reduced by antih ypertensive therapy regardless of medication prior to the trial. Interestingly, treatment was found to be effective in patients over 80 years of age. an age group previously thought not to benefit from antihypertensive therapy. The incidence of cardiovascular events was signit1cantly reduced in patients receiving antihypertensives compared with placebo but no significant reduction in overall mortality occurred. While these results do not yet warrant recommending chlorthalidone as first-line therapy in isolated systolic hypertension, the low cost of such therapy. its apparent efficacy and a low rate of adverse effects make it an appealing choice. Winker MA. Murphy MB. Isolated systolic hypertension in the elderly. Journal of the American Medical Association 265: 3301-3302. 26 Jun M% 6 Jul1991 INPHARMA® ISSN fiI56-1703/91/0706-()OOl/()SiJJ.o% ID Adis International Ltd

Upload: dangkien

Post on 16-Mar-2017

215 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Antihypertensive therapy holds promise for isolated systolic hypertension in the elderly

2

AIit.ihyper,tensive therapy holds promise for isolated systolic hypertension in-the iHderly . . ..

The prevalence of isolated systolic hypertension ranges from ' 6% in 60-year-olds to 180/0 inpatients aged>' 80 years . . Several studies have .shown the efficacy of antihypertensive therapy in elderly patients with isolated systolic hypertension bufthe effect on the risk-of cardiovascular events and adverse metabolic effects was unclear. Results of a 5-yearfollow-up of the Systolic Hypertension in the Elderly Programme [see Therapy section, this issue. p 10] confirm the efficacy and safety of chlorthalidone therapy in patients aged); 60 years with isolated systolic hypertension. The risk of stroke in these patients was found to be significantly reduced by antihypertensive therapy regardless of medication prior to the trial. Interestingly, treatment was found to be effective in patients over 80 years of age. an age group previously thought not to benefit from antihypertensive therapy. The incidence of cardiovascular events was signit1cantly reduced in patients receiving antihypertensives compared with placebo but no significant reduction in overall mortality occurred.

While these results do not yet warrant recommending chlorthalidone as first-line therapy in isolated systolic hypertension, the low cost of such therapy. its apparent efficacy and a low rate of adverse effects make it an appealing choice. Winker MA. Murphy MB. Isolated systolic hypertension in the elderly. Journal of the American Medical Association 265: 3301-3302. 26 Jun I~I M%

6 Jul1991 INPHARMA® ISSN fiI56-1703/91/0706-()OOl/()SiJJ.o% ID Adis International Ltd